FIND A DOCTORFaceTreatmentsBodyHairAwardsShoppingWellnessAbout UsTESTTUBE Advertisement Home›Cosmetic Treatments›Neurotoxins Why This Highly Anticipated Neurotoxin Is Delayed What the FDA flagged, and what happens next. As reported by Dermatology Times, AbbVie and Allergan Aesthetics have announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application for TrenibotulinumtoxinE (TrenibotE). The investigational botulinum neurotoxin serotype E is currently under review for the treatment of moderate to severe glabellar lines.While the CRL delays potential approval, the company emphasized that the agency’s feedback was limited to manufacturing-related issues and did not cite concerns regarding safety or efficacy, nor did it request additional clinical trials.

Read the full article →